GIBSON DUNN

Gibson Dunn Represented Neurogene on $143.7 Million Offering of Common Stock and Pre-Funded Warrants

Firm News | July 17, 2026

Gibson Dunn represented Neurogene Inc., a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases, in a public offering of 4,124,999 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 624,999 shares. The offering also included the issuance to certain investors of pre-funded warrants to purchase up to 666,666 shares of common stock. The offering generated aggregate gross proceeds of approximately $143.7 million to Neurogene.

Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital, and William Blair acted as joint bookrunning managers for the offering.

The Gibson Dunn team included partners Ryan Murr and Branden Berns and associates Lauren Navarro and Jasmine Vitug.

Related People

Ryan A. Murr

Branden C. Berns

Lauren Navarro

Jasmine L. Vitug

Related Capabilities

Capital Markets

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**